Phase 3 study evaluating the safety and efficacy of clazosentan in an aneurysmal subarachnoid haemorrhage (aSAH) population enriched for the risk of cerebral vasospasm.
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Clazosentan (Primary)
- Indications Cerebral vasospasm
- Focus Therapeutic Use
- 08 Feb 2018 New trial record